As a result of its solid and successful experience as partner with the Italian Health System, its significant expansion into international operations and a fundamental commitment to research and development, Kedrion’s line of plasma-derived products is broad and diverse.
With treatments for many rare and debilitating diseases and conditions from hemolytic disease in newborns to immune deficiencies to hemophilia, Kedrion offers a wide and expanding array of treatments and therapies.
PRODUCT PORTFOLIO
HEMATOLOGY/HEMOPHILIA
EMOCLOT/ HUMAFACTOR-8** / HUMACLOT**
Factor VIII/von Willebrand Factor
AIMAFIX/HUMAFACTOR-9**
Factor IX concentrate
UMAN COMPLEX
Prothrombin Complex concentrate
IMMUNOLOGY/NEUROLOGY
Ig VENA/ /HUMAGLOBIN Liquid**
Standard i.v.Immunoglobulin
VENBIG
Anti-hepatitis B i.v. Immunoglobulin
IMMUNOHBs/UMAN BIG
Anti-hepatits B i.v. Immunoglobulin
TETANUS GAMMA/TETIG**
Anti-tetanus i.m. Immunoglobulin
ImmunoRHO/RhoGAM
Anti-D i.m. Immunoglobulin
CRITICAL CARE
UMAN ALBUMIN//HUMAN ALBUMIN
Human Albumin solution
ORPHAN DRUGS
Kedrion Human Plasminogen: a sterile human plasma derived plasminogen preparation in the pharmaceutical form of an eye drop solution for the treatment of Ligneous Conjunctivitis (currently under development product).
At the moment the product obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The clinical trial is still ongoing for the Marketing Authorization approval in the USA and in Europe (EU).
**** not yet available for distribution
*** products only available for the Italian market-
** products only available for the Hungarian market
* products only available for the US market
Where 